Advanced Cell Technology, Inc. (OTC:ACTC) ,sector: Healthcare. industry: Biotechnology
June 12,2009 - Advanced Cell Technology, Inc. (OTC:ACTC) and its collaborators at OHSU reported today the long-term safety and efficacy of human embryonic stem cell (hESC)-derived retinal pigment epithelium (RPE) produced under manufacturing conditions suitable for human clinical trials. Two important early potential hESC applications are the use of RPE for the treatment of age-related macular degeneration and Stargardt disease, an untreatable form of eye disease that leads to early-onset blindness. The research, which appears online ahead of print in the journal Stem Cells, shows long-term functional rescue using hESC-derived cells in both the RCS rat and Elov14 mouse, animal models of retinal degeneration and Stargardt, respectively. The cells survived transplantation for prolonged periods (>220 days) and sustained visual function without tumor formation or untoward pathological reactions. Near-normal functional rescue was also achieved in the 'Stargardt' mouse. To further address safety concerns, a study was carried out in the NIH III immune deficient mouse model. Long-term data (spanning the life of the animals) revealed no evidence of tumor formation after transplantation.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.
About ESR:
Emerging Stock Report is a leading provider of independent investment research in North America our services include, research analysis on the small cap markets, real time news and financial data, market commentary and the ESR newsletter .Emerging Stock Report's staff of small cap investment professionals is dedicated to providing the emerging market's investment community with the tools and avenues necessary to make the important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services go to www.emergingstockreport.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at www.emergingstockreport.com/register.php
ESR Disclosure:
Emerging Stock Report is not a registered investment advisor and nothing in this release should be construed as a recommendation to buy or sell securities. Emerging Stock Report has not been compensated by the above mentioned companies.
CONTACT: Emerging Stock Report e-mail: info@emergingstockreport.com WWW: http://www.emergingstockreport.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index